Selecting the correct model for a preclinical study is one of the most important decisions in early-stage research and development. The choice of model directly influences the reliability, translational value, and regulatory acceptance of the study results. Researchers must first consider the biological relevance of the model to human physiology. For example, certain disease models in rodents may replicate human conditions only partially, while larger animal models may provide closer anatomical or physiological similarity. However, increased similarity often comes with higher cost, ethical considerations, and logistical complexity. Therefore, the selection process must balance scientific accuracy with practical constraints. Another critical factor is the study objective itself, whether it focuses on safety, efficacy, pharmacokinetics, or device performance, as each endpoint may require a different model system.
Beyond biological relevance, technical feasibility and historical data availability also play a significant role in model selection. A model that has been widely validated in previous studies may offer more predictable outcomes and easier regulatory justification. Conversely, novel or custom-developed models may offer higher specificity but carry greater uncertainty. Ethical considerations and compliance with animal welfare regulations must also be incorporated into the decision-making process. Additionally, pilot studies are often useful to evaluate whether a selected model behaves as expected under experimental conditions. Cross-functional collaboration between scientists, veterinarians, and regulatory professionals ensures that the chosen model aligns with both scientific and compliance requirements. Ultimately, the right model improves data quality, reduces study repetition, and strengthens the overall development pathway.
